Olema Pharmaceuticals Announces Positive Clinical Results for Breast Cancer Treatment
Updated Clinical Results Revealed at SABCS 2024
SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced updated clinical results from the ongoing Phase 1b/2 study of palazestrant in combination with CDK4/6 inhibitor, ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Results as of September 25, 2024, will be presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Updated results as of November 11, 2024, are detailed below.
Positive Impact on Patients
The updated clinical results of palazestrant in combination with ribociclib show promising outcomes for patients with ER+/HER2- advanced or metastatic breast cancer. These results demonstrate the potential of this treatment combination to improve outcomes and provide new options for patients facing this challenging disease. Patients may benefit from more effective and targeted therapies that can help manage their cancer and potentially extend their survival.
Global Impact of the Study
The positive clinical results presented by Olema Pharmaceuticals at SABCS 2024 highlight the ongoing innovation and advancement in the field of breast cancer treatment. This study has the potential to impact patients worldwide by introducing new treatment options and advancing our understanding of how targeted therapies can be used to combat breast cancer. The data presented at the conference contribute to the growing body of evidence supporting the development of novel therapies for this prevalent disease.
Conclusion
In conclusion, the updated clinical results from Olema Pharmaceuticals’ Phase 1b/2 study of palazestrant in combination with ribociclib demonstrate the potential of this treatment approach for patients with ER+/HER2- advanced or metastatic breast cancer. These findings have implications not only for individual patients but also for the broader field of oncology research, as they contribute to the growing body of evidence supporting the development of targeted therapies for breast cancer. As the study progresses and additional data is collected, we may see further advancements in the treatment of this complex and challenging disease.
